-
2
-
-
79957486425
-
Variables affecting the quantitation of CD22 in neoplastic B cells
-
Sep 24. [Epub ahead of print]
-
Jasper GA, Arun I, Venzon D, et al. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom 2010 Sep 24. [Epub ahead of print]
-
(2010)
Cytometry B Clin Cytom
-
-
Jasper, G.A.1
Arun, I.2
Venzon, D.3
-
3
-
-
73949120281
-
VH4-34 hairy cell leukemia, a new variant with poor prognosis despite standard therapy
-
Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34 hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687-4695.
-
(2009)
Blood
, vol.114
, pp. 4687-4695
-
-
Arons, E.1
Suntum, T.2
Stetler-Stevenson, M.3
Kreitman, R.J.4
-
4
-
-
0032530684
-
Long-term follow-up of patients with hairy cell leukemia after cladribine treatment
-
Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-1926. (Pubitemid 28446680)
-
(1998)
Blood
, vol.92
, Issue.6
, pp. 1918-1926
-
-
Saven, A.1
Burian, C.2
Koziol, J.A.3
Piro, L.D.4
-
5
-
-
67649933809
-
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia
-
Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27:2983-2990.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2983-2990
-
-
Kreitman, R.J.1
Stetler-Stevenson, M.2
Margulies, I.3
-
6
-
-
55249105262
-
Soluble CD22 as a tumor marker for patients with B-cell malignancies
-
Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ. Soluble CD22 as a tumor marker for patients with B-cell malignancies. Blood 2008;112: 2272-2277.
-
(2008)
Blood
, vol.112
, pp. 2272-2277
-
-
Matsushita, K.1
Margulies, I.2
Onda, M.3
Nagata, S.4
Stetler-Stevenson, M.5
Kreitman, R.J.6
-
9
-
-
0028929938
-
Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study
-
Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995;13:974-982.
-
(1995)
J Clin Oncol
, vol.13
, pp. 974-982
-
-
Grever, M.1
Kopecky, K.2
Foucar, M.K.3
-
10
-
-
66749169284
-
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis
-
Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145:733-740.
-
(2009)
Br J Haematol
, vol.145
, pp. 733-740
-
-
Else, M.1
Dearden, C.E.2
Matutes, E.3
-
11
-
-
0042243678
-
Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia
-
DOI 10.1182/blood-2003-01-0014
-
Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810-813. (Pubitemid 36917768)
-
(2003)
Blood
, vol.102
, Issue.3
, pp. 810-813
-
-
Nieva, J.1
Bethel, K.2
Saven, A.3
-
12
-
-
0035954624
-
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
-
DOI 10.1056/NEJM200107263450402
-
Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241-247. (Pubitemid 32695063)
-
(2001)
New England Journal of Medicine
, vol.345
, Issue.4
, pp. 241-247
-
-
Kreitman, R.J.1
Wilson, W.H.2
Bergeron, K.3
Raggio, M.4
Stetler-Stevenson, M.5
Fitzgerald, D.J.6
Pastan, I.7
-
13
-
-
63049113411
-
Bendamustine: Rebirth of an old drug
-
Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492-501.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1492-501
-
-
Cheson, B.D.1
Rummel, M.J.2
-
14
-
-
77953670179
-
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: Treatment recommendations from an international consensus panel
-
Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010;10:21-27.
-
(2010)
Clin Lymphoma Myeloma Leuk
, vol.10
, pp. 21-27
-
-
Cheson, B.D.1
Wendtner, C.M.2
Pieper, A.3
-
15
-
-
33745075957
-
Eradication of minimal residual disease in hairy cell leukemia
-
DOI 10.1182/blood-2005-11-4590
-
Ravandi F, Jorgensen JL, OBrien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658-4662. (Pubitemid 43882611)
-
(2006)
Blood
, vol.107
, Issue.12
, pp. 4658-4662
-
-
Ravandi, F.1
Jorgensen, J.L.2
O'Brien, S.M.3
Verstovsek, S.4
Koller, C.A.5
Faderl, S.6
Giles, F.J.7
Ferrajoli, A.8
Wierda, W.G.9
Odinga, S.10
Huang, X.11
Thomas, D.A.12
Freireich, E.J.13
Jones, D.14
Keating, M.J.15
Kantarjian, H.M.16
|